logo-loader
viewCB2 Insights Inc.

CB2 Insights set to launch cloud-based platform Sail in 2020

Sail brings together multiple data references into a single platform for licensed producers to improve data efficiencies

pot stocks data
CB2 plans to launch the cloud-based platform in 2020

CB2 Insights Inc (CSE:CBII) (OTCMKTS:CBIIF) is ready to set Sail with its core technology platform aimed at connecting unequal data systems. 

The company’s core technology, Sail, brings together multiple data references from production, retail, medical and product information into a single platform to help licensed producers or operators to improve efficiencies in data handling. 

The data analytics company said that Sail is the cannabis sector’s first cannabinoid-focused healthcare data aggregation tool. 

READ: CB2 Insights implements incentive program for $1.1M of outstanding warrants

CB2 plans to launch the cloud-based platform in 2020, the Toronto-based company said in a Thursday statement.

“As is often seen in healthcare, managing multiple, disparate systems is a large and expensive barrier and often leads to failed attempts at making solid business decisions,” CEO Prad Sekar told investors. “At CB2 we are committed to be the leading company for streamlining, measuring, and generating insightful data to make improvements for the maturing global medical cannabis industry.”

The Sail platform has been used to collect and analyze millions of data points from hundreds of thousands of medical patients using cannabinoid therapy, Sekar said. It is now able to integrate full data inputs from electronic medical record, dispensary, pharmacy systems, and clinical research systems to produce actionable insights, according to the CEO.

“The data lake will integrate a variety of distinct raw data sets sourced from clinical assets, dispensaries, cannabis companies and other key industry suppliers,” CB2’s chief technical officer Kash Qureshi told shareholders.

“Raw anonymized data will be ingested and catalogued, creating a repository that in turn will be a single source to generate insights which can be reviewed and tested over indefinitely and will be key to improving research projects moving forward.”

Earlier this year, CB2 secured technology and data-focused partnerships with Premier Health Group, UK-based Drug Science, MyAccess Clinics, VIVO Cannabis and FCM Global in Colombia.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: CB2 Insights Inc.

Price: 0.14 CAD

CSE:CBII
Market: CSE
Market Cap: $11.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CB2 Insights announces key partnership with GL Brands for...

CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...

on 12/17/2019

2 min read